Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA3325461
Max Phase: Preclinical
Molecular Formula: C20H24F2N4O5S
Molecular Weight: 470.50
Molecule Type: Small molecule
Associated Items:
ID: ALA3325461
Max Phase: Preclinical
Molecular Formula: C20H24F2N4O5S
Molecular Weight: 470.50
Molecule Type: Small molecule
Associated Items:
Canonical SMILES: Cc1nc(S(C)(=O)=O)ccc1Oc1ncnc(OC2CCN(C(=O)C(C)(C)F)CC2)c1F
Standard InChI: InChI=1S/C20H24F2N4O5S/c1-12-14(5-6-15(25-12)32(4,28)29)31-18-16(21)17(23-11-24-18)30-13-7-9-26(10-8-13)19(27)20(2,3)22/h5-6,11,13H,7-10H2,1-4H3
Standard InChI Key: HKJDCMBBABRWKS-UHFFFAOYSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 470.50 | Molecular Weight (Monoisotopic): 470.1435 | AlogP: 2.63 | #Rotatable Bonds: 6 |
Polar Surface Area: 111.58 | Molecular Species: NEUTRAL | HBA: 8 | HBD: 0 |
#RO5 Violations: 0 | HBA (Lipinski): 9 | HBD (Lipinski): 0 | #RO5 Violations (Lipinski): 0 |
CX Acidic pKa: | CX Basic pKa: 0.67 | CX LogP: 1.40 | CX LogD: 1.40 |
Aromatic Rings: 2 | Heavy Atoms: 32 | QED Weighted: 0.63 | Np Likeness Score: -1.11 |
1. Buzard DJ, Kim SH, Lehmann J, Han S, Calderon I, Wong A, Kawasaki A, Narayanan S, Bhat R, Gharbaoui T, Lopez L, Yue D, Whelan K, Al-Shamma H, Unett DJ, Shu HH, Tung SF, Chang S, Chuang CF, Morgan M, Sadeque A, Chu ZL, Leonard JN, Jones RM.. (2014) Discovery and optimization of 5-fluoro-4,6-dialkoxypyrimidine GPR119 agonists., 24 (17): [PMID:25088191] [10.1016/j.bmcl.2014.06.071] |
Source(1):